Results 31 to 40 of about 391 (114)
Psoriasis is a chronic, inflammatory skin disease present in about 3% of the world’s population. The clinical symptoms manifest diversely, therefore one can distinguish several subtypes of psoriasis.
Kamila Jaworecka +12 more
doaj +1 more source
Von Zumbusch’s pustular psoriasis associated with oral terbinafine
Adverse skin reactions have been reported in 2.7% of patients receiving oral terbinafine. Less common but life-threatening reactions include acute generalized exanthematous pustulosis (AGEP), Stevens-Johnson syndrome, toxic epidermal necrolysis ...
Naoufal Hjira +5 more
doaj +1 more source
Dermatologic Best Practices for Manicures and Nail Care: A Systematic Review
ABSTRACT Background Manicure and pedicure procedures are widely viewed as benign cosmetic practices, yet emerging evidence links them to various dermatologic complications, including dermatitis, infection, photodamage and, in rare cases, cutaneous malignancy.
Nivetha Aravind +2 more
wiley +1 more source
Economic Burden of Generalized Pustular Psoriasis: A Population-based Register Study in Finland
Generalized pustular psoriasis is an inflammatory disease characterized by potentially life-threatening flares. This study assessed the economic burden of generalized pustular psoriasis in Finland by comparing healthcare resource utilization and both ...
Xavier Teitsma +9 more
doaj +1 more source
IgA nephropathy in a patient receiving infliximab for generalized pustular psoriasis
Background IgA nephropathy is the most common glomerulonephritis. Secondary IgA nephropathy complicated with systemic diseases, including psoriasis, is also often reported.
Yuka Segawa +9 more
doaj +1 more source
ABSTRACT Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, is approved in multiple countries for the treatment of moderate to severe plaque psoriasis, as well as generalized pustular and erythrodermic psoriasis in Japan. Deucravacitinib 6 mg once daily was efficacious and well tolerated through 3 years in the pooled population of ...
Yukari Okubo +12 more
wiley +1 more source
ABSTRACT Systemic psoriasis treatment options have rapidly expanded in Japan, including the approval of tyrosine kinase 2 and interleukin‐36 receptor inhibitors in 2022. However, contemporary real‐world treatment patterns across plaque, erythrodermic, and generalized pustular psoriasis remain incompletely characterized.
Yayoi Tada +9 more
wiley +1 more source
Systemic Treatment of Psoriasis: Current Evidence on Efficacy and Safety
ABSTRACT Systemic treatments for moderate‐to‐severe plaque psoriasis have been advanced from broad immunosuppressants up to agents more selectively targeting cytokines, cytokine receptors, or intracellular signaling. The current systemic treatments mainly consist of conventional systemic agents, biologics targeting tumor necrosis factor (TNF)‐α ...
Teppei Hagino, Naoko Kanda
wiley +1 more source
Summary Background The Psoriasis Area and Severity Index (PASI) is the standard measure for psoriasis severity but reflects only a single time point and may underestimate long‐term disease burden. To assess whether the highest‐ever recorded PASI (PeakPASI) can serve as a marker of historical disease severity and correlate with treatment burden and ...
Simran Wilkhoo +6 more
wiley +1 more source
S1 Guideline: Therapy of generalized pustular psoriasis
Summary The S1 guideline “Therapy of generalized pustular psoriasis (GPP)” is a German guideline developed in accordance with the criteria of the AWMF. The full version addresses clinical presentation, pathogenesis, diagnosis and differential diagnosis, comorbidities, and therapy.
Rotraut Mößner +17 more
wiley +1 more source

